-
G-1: A Selective GPR30 Agonist Workflow
2026-09-18
Use G-1 to isolate rapid GPR30 signaling from classical estrogen receptor effects in calcium, PIP3, migration, and cardiac studies. This practical guide combines nanomolar assay design, heart failure model considerations, and mechanistic controls inspired by recent GPER research.
-
Targeted Amikacin Delivery into Mycobacterial Granulomas
2026-09-18
The reference study demonstrated that monocyte-derived dendritic cells can carry fluorescently labeled amikacin into Mycobacterium avium–associated granulomas in infected mice. Its main contribution is a proof of concept for organism-directed antibiotic delivery that may increase local drug exposure while reducing reliance on toxic systemic dosing.
-
Miltefosine and Ras/MEK/ERK in Leukopenia
2026-09-17
The reference study identifies Miltefosine as a candidate regulator of neutrophil differentiation, linking its activity to Ras/MEK/ERK signaling rather than only to its previously studied phospholipid or oncology roles. Using leukemia cell models, irradiation-induced leukopenic mice, transcriptomics, network pharmacology, docking, and pathway inhibition, the authors show improved granulocytic maturation and hematopoietic recovery while establishing important limits for translation.
-
4-Hydroxytamoxifen: DMSO Workflow Guide
2026-09-17
4-Hydroxytamoxifen (SKU B6167) provides an estrogen receptor modulator for controlled, DMSO-based cell and cardiac myocyte workflows. It is appropriate for exploratory breast cancer research, prostate cancer research, and receptor-linked assays, but it should not be selected for protocols requiring water or ethanol solubilization.
-
BEND Lipids Improve mRNA and CRISPR Delivery
2026-09-16
The reference study introduces branched endosomal disruptor (BEND) ionizable lipids as a structural strategy for improving lipid nanoparticle delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes. Across hepatic gene-editing and T-cell engineering contexts, branched lipids outperformed non-branched comparators and were associated with enhanced endosomal penetration and disruption.
-
BAPTA for Mechanistic Calcium Signaling Assays
2026-09-15
BAPTA is a high-affinity calcium chelator for separating intracellular Ca2+ signaling from downstream apoptosis. This guide translates recent IP3R/Ca2+/STAT3 findings into a rigorous assay design and interpretation framework.
-
Dual Enzyme-Responsive Peptides for Cancer Selectivity
2026-09-15
A 2026 Biomacromolecules study reports a zwitterionic peptide amphiphile that uses sequential MMP-7-triggered disassembly and cathepsin B-directed intralysosomal assembly to improve cancer selectivity. The design produced a cancer selectivity index of 64.1, low-micromolar activity, and tumor regression in an HT-29 xenograft model, while highlighting important questions about enzyme heterogeneity and translational scope.
-
Tofacitinib citrate: Applied JAK3 Research Workflows
2026-09-14
Tofacitinib citrate (CP-690550 citrate) supports concentration-controlled studies of JAK-STAT signaling, lymphocyte function, and cytokine-driven inflammation. This guide distinguishes low-nanomolar immune-cell workflows from higher-dose endothelial stress experiments, helping researchers select informative controls and avoid misreading vascular or cytotoxicity signals.
-
Ruthenium Red in Mechanotransduction Assays
2026-09-14
Ruthenium Red is a versatile Ca2+ transport inhibitor for testing whether calcium flux contributes to mechanically induced autophagy. This article translates cytoskeleton-dependent findings into a rigorous assay-design framework while distinguishing established evidence from testable mechanistic extensions.
-
JIB-04 Targets Colorectal Cancer Stem Cells
2026-09-13
The reference study identifies JIB-04 as a pan-selective Jumonji-family histone demethylase inhibitor that preferentially suppresses colorectal cancer stem cell properties. Using tumorsphere, molecular, and tumorigenicity assays, the authors connect JIB-04 activity with reduced Wnt/β-catenin signaling, providing a mechanistic framework for targeting relapse-associated colorectal cancer cell populations.
-
Glutamine Metabolism in Hepatic Stellate Cells
2026-09-12
The reference study identifies the SIRT4–GDH metabolic axis as a regulator of hepatic stellate cell activation and liver fibrosis. By combining pharmacological GDH inhibition with SIRT4 overexpression in cellular and animal models, the authors show that restricting glutamate conversion to α-ketoglutarate can reduce fibrogenic activity.
-
Erlotinib and SCUBE3: Mapping Resistance at EGFR
2026-09-12
SCUBE3 links extracellular signaling, EGFR activity, therapy resistance, and immune suppression. This thought-leadership guide explains how Erlotinib can help translational researchers test the EGFR-dependent component of that biology while preserving a clear distinction between pathway inhibition and direct SCUBE3 neutralization.
-
X-Gal: From Clone Selection to Translational Insight
2026-09-11
X-Gal is more than a blue-white colony screening reagent: it is a practical control point for construct quality, reporter validation, and translational decision-making. This article connects the enzymatic logic of 5-bromo-4-chloro-indolyl-β-D-galactopyranoside with emerging insights into iRhom2, ADAM17, olfactory receptors, and activity-dependent adaptation.
-
BAPTA: A Causal Tool for Calcium Signaling
2026-09-11
Explore how BAPTA functions as a calcium chelator for causal calcium signaling studies, with a focused analysis of IP3R/Ca2+/STAT3-dependent apoptosis. This guide translates recent toxicology findings into better assay design, controls, and interpretation.
-
YC-1: A Decision Framework for Hypoxia Assays
2026-09-10
YC-1 is a dual-action sGC activator and HIF-1α research probe for cancer biology. This guide presents an assay-triangulation framework that separates hypoxia signaling, cGMP effects, fluorescence artifacts, and cell-death outcomes.